ASCO 2020：11项中国人研究入选口头报告，17项Poster报告

倍受全球新冠传染病影响，原定于5年底29日~6年底2日在芝加哥举行的美国临床学则会（ASCO）年则会今年将首次以两条路线上形式举办，这是目前为止最大规模的两条路线上盛则会。今天，开则会的简介题目公布，共103个sessions，西方仅有11项分析被选为口头报告，17项被选为Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或佩佩替尼加卡培他滨用以HER2+乳腺癌肠腹腔癌（PHOEBE）：一项III期随机试验车。

首站：乳腺癌肠腹腔癌

所作：西方医学科学院所医院徐兵河任教、马飞任教，武汉大学附属所医院胡夕春任教等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴性肠腹腔癌规格病患后卡培他滨可维持快节奏疗程的III期试验车（SYSUCC-001）。

首站：肠腹腔癌—区外内/区外/借助于病患

所作：里面山大学公共卫生里面心王时树森任教等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

并用乳腺癌脑的遗传基因特点来预测脑脊液里面循环DNA检验的概率: 新用以敌对杨家对手

首站：新用以解决杨家疑虑

所作：朱美芹 朱德兰等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对比索拉非尼作为中晚期肠两条路线粒体腹腔癌的三两条路线病患：一项对外开放ID、随机、多里面心II/III期试验车。

首站：中枢神经腹腔癌—腹腔静脉、血栓和实为

所作：浙江大学亚东所医院毕锋任教、西方当权者解放军南开所医院秦叔逵任教等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

西方中晚期肠腹腔癌患儿阿帕替尼三两条路线病患：一项随机、CPA相异、测试者III期分析

首站：中枢神经腹腔癌—腹腔静脉、血栓和实为

所作：西方当权者解放军南开所医院秦叔逵任教、浙江大学亚东所医院朱秋任教等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中晚期开刀性卵巢腹腔癌二次两条路线粒体减灭术的一项随机III期试验车：SOC1 / SGOG-OV2。

不定期：针灸腹腔帕金森氏症

所作：武汉大学附属里面山所医院臧荣余任教等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈腹腔癌根治性子宫切除术后借助于病患里面的序贯放疗程对比单独放疗或同步放疗程（STARS分析）：一项随机、相异、对外开放ID的III期试验车。

开则会：针灸腹腔帕金森氏症

所作：里面山大学公共卫生里面心凌云任教、刘继红任教等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：借助于吉非替尼对比疗程用以可切除的EGFR基因突变的N1-N2期NSCLC-随机III期临床试验车的最终整体而言求生分析。

不定期：肠腹腔癌—非小两条路线粒体区外内-区外/小两条路线粒体/其他胸部

所作：广东省当权者所医院吴一龙任教等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因突变寡集中于非小两条路线粒体肠腹腔癌患儿三两条路线赖氨酸集中于酶药物倡议或不倡议积极第一两条路线区外内放疗：III期对外开放ID临床随机试验车（SINDAS）的里面期结果（NCT02893332）。

不定期：肠腹腔癌-非小两条路线粒体集中于

所作：四川省当权者所医院曾铭任教等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对某类死亡-1（PD-1）的人源化IgG4化学疗法倡议阿昔替尼用以乳腺癌皮肤黑色素结节患儿的Ib期分析的总求生期和生物标志物分析。

不定期：黑色素结节/皮肤腹腔癌

所作：北京大学所医院郭军、盛锡楠任教等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的实用性和结果：常用CAR-T两条路线粒体首次人体试验车病患开刀/难治性T两条路线粒体急性淋巴两条路线粒体帕金森氏症（r/r T-ALL）的实用性和。开则会：技术开发里面的病患关键技术-免疫病患。所作：王时欣欣等简介：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利他汀在中晚期静脉结节两条路线粒体腹腔癌患儿里面的领域：一项随机的对外开放IDII期试验车（ORIENT-2）。开则会：中枢神经腹腔癌-腹腔静脉腹腔癌、血栓腹腔癌和实为道腹腔癌所作：徐建明任教等简介：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异性CAR-T两条路线粒体对炎母两条路线粒体结节的消弭性病患开则会：里面枢神经系统所作：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、姚旭东简介：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中晚期错配修复缺陷患儿里面的领域开则会：技术开发里面的病患学-免疫病患所作：沈琳任教等简介：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART病患开刀/难治性ACUTE淋巴两条路线粒体帕金森氏症/淋巴结节的首例人体临床试验车开则会: 技术开发性病患学-免疫病患所作简介：张明志，杨林等简介：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议领域以中晚期也就是说结节患儿的Ib期分析开则会：发展性病患学便是分子凋亡药物和病理学所作：龚继芳，沈琳任教等简介：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议嘌呤和nedaplatin病患开刀性或乳腺癌静脉结节两条路线粒体腹腔癌（ESCC）患儿的II期分析。开则会：中枢神经腹腔癌-腹腔静脉、血栓和实为道腹腔癌的分析所作：王时志最弱，朱玉红，王时德申，王时凤华，任超，谭琼 王时志最弱、朱玉红、王时德深、王时凤华、任超、谭琼简介：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.开则会：中枢神经腹腔癌-腹腔静脉腹腔癌、血栓腹腔癌和实为管腹腔癌的三两条路线病患所作：宋艳等简介：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种体液外体外缘RNA权重用以初始活检时检验高等级腹腔癌的体液外体外缘RNA权重：一项多里面心的回顾性分析开则会：泌尿生殖系统腹腔帕金森氏症便是-腹腔癌、睾丸腹腔癌和腹腔癌所作简介：Liaoyuan Li等简介：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 区外内中晚期宫颈腹腔癌比方说疗程后的借助于疗程开则会: 针灸腹腔帕金森氏症所作简介： 朱珉珉等简介：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病患肾脏炎性腹腔癌的相似性：基于ALTER01031试验车的分析。则会衹：黑纹所作：天津市所医院老练任教简介：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、较小和成年对安洛替尼病患后患儿命运的影响: ALTER01031的亚组分析开则会：黑纹所作：天津市所医院老练任教简介：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA分析预测I-IIIA期非小两条路线粒体肠腹腔癌（NSCLC）患儿术后开刀: GASTO1035和GASTO1018的结果开则会：肠腹腔癌-非小两条路线粒体区外内-区外性/小两条路线粒体/小两条路线粒体/其他胸科腹腔帕金森氏症所作：Si-Yu Wang等简介：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小两条路线粒体肠腹腔癌（NSCLC）里面EGFR赖氨酸集中于酶药物的新型耐药有助于开则会:肠腹腔癌-非小两条路线粒体乳腺癌肠腹腔癌所作简介：姚昕，金MLT-，满宇，欧西厢记，湛，薛武，杨少，范敏 姚昕、金MLT-、满宇、欧西厢记、湛、薛武、杨绍、范敏简介：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验车里面后期黑色素结节总求生的替代终点开则会：黑色素结节/皮肤腹腔癌所作：聂润聪，袁书最弱，朱元芳，陈英波，周志伟 聂润聪、袁书最弱、朱元芳、陈英波、周志伟简介：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病患开刀或乳腺癌继发性恶性头骨患儿的II期分析开则会： 病变所作：唐丽娜，牛晓辉，王时震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王时振、蔡启庆、涂崇奇、范正福、杨瑶简介：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评分安罗替尼在中晚期病变患儿多两条路线病患里面的实用性和。开则会：病变所作：姚伟涛，王时家最弱，张鹏，王时欣，杜新辉，田志浩，牛晓颖 姚伟涛、王时家最弱、张鹏、王时鑫、杜鑫辉、田志超、牛晓英简介：11526广告：414